TY - JOUR AU - Siegel, R. L. AU - Miller, K. D. AU - Jemal, A. PY - 2018 DA - 2018// TI - Cancer statistics, 2018 JO - CA Cancer J Clin VL - 68 UR - https://doi.org/10.3322/caac.21442 DO - 10.3322/caac.21442 ID - Siegel2018 ER - TY - JOUR AU - Bauer, K. R. AU - Brown, M. AU - Cress, R. D. AU - Parise, C. A. AU - Caggiano, V. PY - 2007 DA - 2007// TI - Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry JO - Cancer. VL - 109 UR - https://doi.org/10.1002/cncr.22618 DO - 10.1002/cncr.22618 ID - Bauer2007 ER - TY - JOUR AU - Carey, L. A. AU - Perou, C. M. AU - Livasy, C. A. AU - Dressler, L. G. AU - Cowan, D. PY - 2006 DA - 2006// TI - Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study JO - JAMA. VL - 295 UR - https://doi.org/10.1001/jama.295.21.2492 DO - 10.1001/jama.295.21.2492 ID - Carey2006 ER - TY - JOUR AU - Dent, R. AU - Trudeau, M. AU - Pritchard, K. I. AU - Hanna, W. M. AU - Kahn, H. K. PY - 2007 DA - 2007// TI - Triple-negative breast cancer: clinical features and patterns of recurrence JO - Clin Cancer Res VL - 13 UR - https://doi.org/10.1158/1078-0432.CCR-06-3045 DO - 10.1158/1078-0432.CCR-06-3045 ID - Dent2007 ER - TY - STD TI - National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): breast cancer (Version 1.2019). Accessed 8 July 2019. ID - ref5 ER - TY - JOUR AU - Cardoso, F. AU - Senkus, E. AU - Costa, A. AU - Papadopoulos, E. AU - Aapro, M. PY - 2018 DA - 2018// TI - 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4) JO - Ann Oncol VL - 29 UR - https://doi.org/10.1093/annonc/mdy192 DO - 10.1093/annonc/mdy192 ID - Cardoso2018 ER - TY - JOUR AU - Zeichner, S. B. AU - Terawaki, H. AU - Gogineni, K. PY - 2016 DA - 2016// TI - A review of systemic treatment in metastatic triple-negative breast cancer JO - Breast Cancer VL - 10 ID - Zeichner2016 ER - TY - JOUR AU - Piccart-Gebhart, M. J. AU - Burzykowski, T. AU - Buyse, M. AU - Sledge, G. AU - Carmichael, J. PY - 2008 DA - 2008// TI - Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2007.10.8399 DO - 10.1200/JCO.2007.10.8399 ID - Piccart-Gebhart2008 ER - TY - JOUR AU - Twelves, C. AU - Cortes, J. AU - Vahdat, L. AU - Olivo, M. AU - He, Y. AU - Kaufman, P. A. AU - Awada, A. PY - 2014 DA - 2014// TI - Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies JO - Breast Cancer Res Treat VL - 148 UR - https://doi.org/10.1007/s10549-014-3144-y DO - 10.1007/s10549-014-3144-y ID - Twelves2014 ER - TY - JOUR AU - Schmid, P. AU - Adams, S. AU - Rugo, H. S. AU - Schneeweiss, A. AU - Barrios, C. H. PY - 2018 DA - 2018// TI - Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer JO - N Engl J Med VL - 379 UR - https://doi.org/10.1056/NEJMoa1809615 DO - 10.1056/NEJMoa1809615 ID - Schmid2018 ER - TY - STD TI - TECENTRIQ® (atezolizumab) injection, for intravenous use [prescribing information]. South San Francisco, CA, USA: Genentech, Inc.; 2019. ID - ref11 ER - TY - STD TI - National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): breast cancer (Version 1.2016). Accessed 8 July 2019. ID - ref12 ER - TY - JOUR AU - Pivot, X. AU - Marme, F. AU - Koenigsberg, R. AU - Guo, M. AU - Berrak, E. AU - Wolfer, A. PY - 2016 DA - 2016// TI - Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy JO - Ann Oncol VL - 27 UR - https://doi.org/10.1093/annonc/mdw203 DO - 10.1093/annonc/mdw203 ID - Pivot2016 ER - TY - JOUR AU - Dent, R. AU - Seock-Ah, I. M. AU - Espie, M. AU - Blau, S. AU - Tan, A. R. PY - 2018 DA - 2018// TI - Overall survival (OS) update of the double-blind placebo (PBO)-controlled randomized phase 2 LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for locally advanced/metastatic triple-negative breast cancer (mTNBC) JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2018.36.15_suppl.1008 DO - 10.1200/JCO.2018.36.15_suppl.1008 ID - Dent2018 ER - TY - JOUR AU - Kim, S. B. AU - Dent, R. AU - Im, S. A. AU - Espie, M. AU - Blau, S. PY - 2017 DA - 2017// TI - Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial JO - Lancet Oncol VL - 18 UR - https://doi.org/10.1016/S1470-2045(17)30450-3 DO - 10.1016/S1470-2045(17)30450-3 ID - Kim2017 ER - TY - JOUR AU - Litton, J. K. AU - Rugo, H. S. AU - Ettl, J. AU - Hurvitz, S. A. AU - Gonçalves, A. PY - 2018 DA - 2018// TI - Talazoparib in patients with advanced breast cancer and a germline BRCA mutation JO - N Engl J Med VL - 379 UR - https://doi.org/10.1056/NEJMoa1802905 DO - 10.1056/NEJMoa1802905 ID - Litton2018 ER - TY - JOUR AU - Robson, M. AU - Im, S. A. AU - Senkus, E. AU - Xu, B. AU - Domchek, S. M. PY - 2017 DA - 2017// TI - Olaparib for metastatic breast cancer in patients with a germline BRCA mutation JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/NEJMoa1706450 DO - 10.1056/NEJMoa1706450 ID - Robson2017 ER - TY - JOUR AU - Robson, M. E. AU - Tung, N. AU - Conte, P. AU - Im, S. A. AU - Senkus, E. PY - 2019 DA - 2019// TI - OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer JO - Ann Oncol VL - 30 UR - https://doi.org/10.1093/annonc/mdz012 DO - 10.1093/annonc/mdz012 ID - Robson2019 ER - TY - JOUR AU - Tutt, A. AU - Tovey, H. AU - Cheang, M. C. U. AU - Kernaghan, S. AU - Kilburn, L. PY - 2018 DA - 2018// TI - Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial JO - Nat Med VL - 24 UR - https://doi.org/10.1038/s41591-018-0009-7 DO - 10.1038/s41591-018-0009-7 ID - Tutt2018 ER - TY - JOUR AU - DerSimonian, R. AU - Laird, N. PY - 1986 DA - 1986// TI - Meta-analysis in clinical trials JO - Control Clin Trials VL - 7 UR - https://doi.org/10.1016/0197-2456(86)90046-2 DO - 10.1016/0197-2456(86)90046-2 ID - DerSimonian1986 ER - TY - JOUR AU - Liberati, A. AU - Altman, D. G. AU - Tetzlaff, J. AU - Mulrow, C. AU - Gotzsche, P. C. PY - 2009 DA - 2009// TI - The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration JO - PLoS Med VL - 6 UR - https://doi.org/10.1371/journal.pmed.1000100 DO - 10.1371/journal.pmed.1000100 ID - Liberati2009 ER - TY - JOUR AU - Vermorken, J. B. AU - Herbst, R. S. AU - Leon, X. AU - Amellal, N. AU - Baselga, J. PY - 2008 DA - 2008// TI - Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies JO - Cancer. VL - 112 UR - https://doi.org/10.1002/cncr.23442 DO - 10.1002/cncr.23442 ID - Vermorken2008 ER - TY - JOUR AU - Aftimos, P. AU - Polastro, L. AU - Ameye, L. AU - Jungels, C. AU - Vakili, J. PY - 2016 DA - 2016// TI - Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial JO - Eur J Cancer VL - 60 UR - https://doi.org/10.1016/j.ejca.2016.03.010 DO - 10.1016/j.ejca.2016.03.010 ID - Aftimos2016 ER - TY - JOUR AU - Awada, A. AU - Bondarenko, I. N. AU - Bonneterre, J. AU - Nowara, E. AU - Ferrero, J. M. PY - 2014 DA - 2014// TI - A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC) JO - Ann Oncol VL - 25 UR - https://doi.org/10.1093/annonc/mdu025 DO - 10.1093/annonc/mdu025 ID - Awada2014 ER - TY - JOUR AU - Baselga, J. AU - Gomez, P. AU - Greil, R. AU - Braga, S. AU - Climent, M. A. PY - 2013 DA - 2013// TI - Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2012.46.2408 DO - 10.1200/JCO.2012.46.2408 ID - Baselga2013 ER - TY - JOUR AU - Brufsky, A. AU - Valero, V. AU - Tiangco, B. AU - Dakhil, S. AU - Brize, A. PY - 2012 DA - 2012// TI - Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial JO - Breast Cancer Res Treat VL - 133 UR - https://doi.org/10.1007/s10549-012-2008-6 DO - 10.1007/s10549-012-2008-6 ID - Brufsky2012 ER - TY - JOUR AU - Isakoff, S. J. AU - Mayer, E. L. AU - He, L. AU - Traina, T. A. AU - Carey, L. A. PY - 2015 DA - 2015// TI - TBCRC009: a multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.57.6660 DO - 10.1200/JCO.2014.57.6660 ID - Isakoff2015 ER - TY - JOUR AU - Miles, D. W. AU - Dieras, V. AU - Cortes, J. AU - Duenne, A. A. AU - Yi, J. AU - O'Shaughnessy, J. PY - 2013 DA - 2013// TI - First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients JO - Ann Oncol VL - 24 UR - https://doi.org/10.1093/annonc/mdt276 DO - 10.1093/annonc/mdt276 ID - Miles2013 ER - TY - JOUR AU - Perez, E. A. AU - Awada, A. AU - O'Shaughnessy, J. AU - Rugo, H. S. AU - Twelves, C. PY - 2015 DA - 2015// TI - Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial JO - Lancet Oncol. VL - 16 UR - https://doi.org/10.1016/S1470-2045(15)00332-0 DO - 10.1016/S1470-2045(15)00332-0 ID - Perez2015 ER - TY - JOUR AU - Pivot, X. B. AU - Li, R. K. AU - Thomas, E. S. AU - Chung, H. C. AU - Fein, L. E. PY - 2009 DA - 2009// TI - Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer JO - Eur J Cancer VL - 45 UR - https://doi.org/10.1016/j.ejca.2009.07.015 DO - 10.1016/j.ejca.2009.07.015 ID - Pivot2009 ER - TY - JOUR AU - Sparano, J. A. AU - Vrdoljak, E. AU - Rixe, O. AU - Xu, B. AU - Manikhas, A. PY - 2010 DA - 2010// TI - Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2009.24.4244 DO - 10.1200/JCO.2009.24.4244 ID - Sparano2010 ER - TY - JOUR AU - Tredan, O. AU - Campone, M. AU - Jassem, J. AU - Vyzula, R. AU - Coudert, B. PY - 2015 DA - 2015// TI - Ixabepilone alone or with cetuximab as first-line treatment for advanced/metastatic triple-negative breast cancer JO - Clin Breast Cancer VL - 15 UR - https://doi.org/10.1016/j.clbc.2014.07.007 DO - 10.1016/j.clbc.2014.07.007 ID - Tredan2015 ER - TY - JOUR AU - Minckwitz, G. AU - Puglisi, F. AU - Cortes, J. AU - Vrdoljak, E. AU - Marschner, N. PY - 2014 DA - 2014// TI - Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial JO - Lancet Oncol. VL - 15 UR - https://doi.org/10.1016/S1470-2045(14)70439-5 DO - 10.1016/S1470-2045(14)70439-5 ID - Minckwitz2014 ER - TY - JOUR AU - Brodowicz, T. AU - Lang, I. AU - Kahan, Z. AU - Greil, R. AU - Beslija, S. PY - 2014 DA - 2014// TI - Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses JO - Br J Cancer VL - 111 UR - https://doi.org/10.1038/bjc.2014.504 DO - 10.1038/bjc.2014.504 ID - Brodowicz2014 ER - TY - JOUR AU - Dieras, V. AU - Campone, M. AU - Yardley, D. A. AU - Romieu, G. AU - Valero, V. PY - 2015 DA - 2015// TI - Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer JO - Ann Oncol VL - 26 UR - https://doi.org/10.1093/annonc/mdv263 DO - 10.1093/annonc/mdv263 ID - Dieras2015 ER - TY - JOUR AU - Fan, Y. AU - Xu, B. H. AU - Yuan, P. AU - Ma, F. AU - Wang, J. Y. PY - 2013 DA - 2013// TI - Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer JO - Ann Oncol VL - 24 UR - https://doi.org/10.1093/annonc/mds603 DO - 10.1093/annonc/mds603 ID - Fan2013 ER - TY - JOUR AU - Halim, I. I. A. AU - El-Sadda, W. AU - El-Ebrashy, M. AU - Ashry, M. PY - 2016 DA - 2016// TI - Phase II study of weekly paclitaxel and carboplatin followed by oral navelbine in patients with triple negative metastatic/recurrent breast cancer previously treated with adjuvant anthracycline and taxotere JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2016.34.15_suppl.e12557 DO - 10.1200/JCO.2016.34.15_suppl.e12557 ID - Halim2016 ER - TY - JOUR AU - Li, Q. AU - Li, Q. AU - Zhang, P. AU - Yuan, P. AU - Wang, J. PY - 2015 DA - 2015// TI - A phase II study of capecitabine plus cisplatin in metastatic triple-negative breast cancer patients pretreated with anthracyclines and taxanes JO - Cancer Biol Ther VL - 16 UR - https://doi.org/10.1080/15384047.2015.1095400 DO - 10.1080/15384047.2015.1095400 ID - Li2015 ER - TY - JOUR AU - Liao, Y. AU - Fan, Y. AU - Wan, Y. AU - Li, J. AU - Peng, L. PY - 2013 DA - 2013// TI - Acceptable but limited efficacy of capecitabine-based doublets in the first-line treatment of metastatic triple-negative breast cancer: a pilot study JO - Chemotherapy. VL - 59 UR - https://doi.org/10.1159/000356156 DO - 10.1159/000356156 ID - Liao2013 ER - TY - JOUR AU - O'Shaughnessy, J. AU - Schwartzberg, L. AU - Danso, M. A. AU - Miller, K. D. AU - Rugo, H. S. PY - 2014 DA - 2014// TI - Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer JO - J Clin Oncol VL - 32 UR - https://doi.org/10.1200/JCO.2014.55.2984 DO - 10.1200/JCO.2014.55.2984 ID - O'Shaughnessy2014 ER - TY - JOUR AU - Rugo, H. S. AU - Barry, W. T. AU - Moreno-Aspitia, A. AU - Lyss, A. P. AU - Cirrincione, C. PY - 2015 DA - 2015// TI - Randomized phase III trial of paclitaxel once per week compared with nanoparticle albumin-bound nab-paclitaxel once per week or ixabepilone with bevacizumab as first-line chemotherapy for locally recurrent or metastatic breast cancer: CALGB 40502/NCCTG N063H (Alliance) JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.59.5298 DO - 10.1200/JCO.2014.59.5298 ID - Rugo2015 ER - TY - JOUR AU - Robert, N. J. AU - Dieras, V. AU - Glaspy, J. AU - Brufsky, A. M. AU - Bondarenko, I. PY - 2011 DA - 2011// TI - RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer JO - J Clin Oncol VL - 29 UR - https://doi.org/10.1200/JCO.2010.28.0982 DO - 10.1200/JCO.2010.28.0982 ID - Robert2011 ER - TY - JOUR AU - Carey, L. A. AU - Rugo, H. S. AU - Marcom, P. K. AU - Mayer, E. L. AU - Esteva, F. J. PY - 2012 DA - 2012// TI - TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2010.34.5579 DO - 10.1200/JCO.2010.34.5579 ID - Carey2012 ER - TY - JOUR AU - Duda, D. G. AU - Ziehr, D. R. AU - Guo, H. AU - Ng, M. AU - Barry, W. T. PY - 2016 DA - 2016// TI - Effect of cabozantinib treatment on circulating immune cell populations in patients with metastatic triple-negative breast cancer (TNBC) JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2016.34.15_suppl.1093 DO - 10.1200/JCO.2016.34.15_suppl.1093 ID - Duda2016 ER - TY - JOUR AU - Hu, X. AU - Zhang, J. AU - Xu, B. AU - Jiang, Z. AU - Ragaz, J. PY - 2014 DA - 2014// TI - Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer JO - Int J Cancer VL - 135 UR - https://doi.org/10.1002/ijc.28829 DO - 10.1002/ijc.28829 ID - Hu2014 ER - TY - JOUR AU - Tolaney, S. M. AU - Tan, S. AU - Guo, H. AU - Barry, W. AU - Van, A. E. PY - 2015 DA - 2015// TI - Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer JO - Investig New Drugs VL - 33 UR - https://doi.org/10.1007/s10637-015-0269-8 DO - 10.1007/s10637-015-0269-8 ID - Tolaney2015 ER - TY - JOUR AU - Tutt, A. AU - Robson, M. AU - Garber, J. E. AU - Domchek, S. M. AU - Audeh, M. W. PY - 2010 DA - 2010// TI - Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial JO - Lancet. VL - 376 UR - https://doi.org/10.1016/S0140-6736(10)60892-6 DO - 10.1016/S0140-6736(10)60892-6 ID - Tutt2010 ER - TY - JOUR AU - Emens, L. A. AU - Braiteh, F. S. AU - Cassier, P. AU - Delord, J. -. P. AU - Eder, J. P. PY - 2015 DA - 2015// TI - Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC) JO - Cancer Res VL - 75 ID - Emens2015 ER - TY - JOUR AU - Adams, S. AU - Schmid, P. AU - Rugo, H. S. AU - Winer, E. P. AU - Loirat, D. PY - 2017 DA - 2017// TI - Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2017.35.15_suppl.1008 DO - 10.1200/JCO.2017.35.15_suppl.1008 ID - Adams2017 ER - TY - STD TI - National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): breast cancer (Version 1.2018). Accessed 8 July 2019. ID - ref50 ER - TY - JOUR AU - Schmid, P. AU - Abraham, J. AU - Chan, S. AU - Wheatley, D. AU - Brunt, M. PY - 2018 DA - 2018// TI - AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): a randomised, double-blind, placebo-controlled, phase II trial JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2018.36.15_suppl.1007 DO - 10.1200/JCO.2018.36.15_suppl.1007 ID - Schmid2018 ER - TY - STD TI - Bardia A, Vahdat L, Diamond J, Kalinsky K, O'Shaughnessy J, et al. Abstract GS1–07: Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate, as ≥3rd-line therapeutic option for patients with relapsed/refractory metastatic triple-negative breast cancer (mTNBC): efficacy results [abstract]. Cancer Res. 2018;78(suppl 4):Abstract GS1-07. ID - ref52 ER - TY - JOUR AU - Yardley, D. A. AU - Weaver, R. AU - Melisko, M. E. AU - Saleh, M. N. AU - Arena, F. P. PY - 2015 DA - 2015// TI - EMERGE: a randomized phase II study of the antibody-drug conjugate glembatumumab vedotin in advanced glycoprotein NMB-expressing breast cancer JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.56.2959 DO - 10.1200/JCO.2014.56.2959 ID - Yardley2015 ER - TY - JOUR AU - Vahdat, L. T. AU - Forero-Torres, A. AU - Schmid, P. AU - Blackwell, K. AU - Telli, M. L. PY - 2019 DA - 2019// TI - A randomized international phase 2b study of the antibody-drug conjugate (ADC) glembatumumab vedotin (GV) in gpNMB-overexpressing, metastatic, triple-negative breast cancer (mTNBC) JO - J Clin Oncol VL - 79 ID - Vahdat2019 ER -